[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-343931-105":3,"doc-detail-343931-en":81,"detail-sidebar-cat-0-en-105":116},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","long-term-safety-of-selpercatinib-for-ret-activated-advanced-solid-tumors-in-libretto-001-differing-patterns-of-adverse-events-over-time","Long-term safety of selpercatinib for RET-activated advanced solid tumors in LIBRETTO-001 - differing patterns of adverse events over time","","Selpercatinib, a selective RET inhibitor approved for RET-activated cancers, was evaluated for long-term clinical safety in the safety population of LIBRETTO-001. A post hoc analysis summarized adverse events over extended follow-up in an ongoing phase I/II single-arm open-label trial. Among 837 patients, grade ≥3 treatment-emergent AEs occurred in 76.2%, with serious AEs in 51.4%. Adverse-event timing shifted with treatment duration, and events were reversible or manageable via dose modifications, supporting continued therapy for most patients.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/long-term-safety-of-selpercatinib-for-ret-activated-advanced-solid-tumors-in-libretto-001-differing-patterns-of-adverse-events-over-time/343931/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/long-term-safety-of-selpercatinib-for-ret-activated-advanced-solid-tumors-in-libretto-001-differing-patterns-of-adverse-events-over-time/343931.png","ImageObject",300,407,{"name":42,"@type":43},"Seraphina","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the purpose of this post hoc analysis of LIBRETTO-001?","Question",{"text":63,"@type":64},"To characterize the clinical safety profile of selpercatinib after long-term follow-up in the safety population of the LIBRETTO-001 trial.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were adverse events distributed by treatment duration?",{"text":68,"@type":64},"Any-grade adverse events showed differing patterns over time: common events before 6 months differed from those at ≥24 months, indicating that AE timing evolved during prolonged treatment.",{"name":70,"@type":61,"acceptedAnswer":71},"Were adverse events manageable during long-term therapy?",{"text":72,"@type":64},"Yes. The analysis reports that adverse events were generally reversible or manageable with dose modifications, enabling most patients to continue treatment safely.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},343931,1790146806,{"code":4,"msg":82,"data":83},"success",{"doc_id":79,"user_id":84,"nickname":42,"user_avatar":85,"doc_module":4,"category_id":86,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":87,"file_id":88,"file_url":89,"file_type":90,"file_size":91,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":92,"language":93,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":94,"faqs":95,"seo_title":96,"seo_description":12,"update_tm":97,"read_time":98,"preview_page_count":33,"preview_urls":99},962075114101,"https://ap-avatar.wpscdn.com/avatar/e000253a75eb197efd?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780044092746381165",8,"Long-term safety of selpercatinib for Rearranged during transfection (RET)-activated advanced solid tumors in LIBRETTO-001: differing patterns of adverse events overtime  \nLuis E. Raez*, 1,, Ashish C. Massey2, Scott S. Barker2, Patrick M. Peterson2, Katherine Liming2, Nathan A. Pennell3  \n1Thoracic Oncology Program, Memorial Cancer Institute, Florida Atlantic University (FAU), Pembroke Pines, FL 33026, United States, 2Eli Lilly and Co., Indianapolis, IN, 46285, United States,  \n3Thoracic Oncology Program, Cleveland Clinic, Cleveland, OH, 44195, United States  \n* Corresponding author: Luis E. Raez, MD, FACP, FCCP, Thoracic Oncology Program at Memorial Cancer Institute, 12235 Pines Boulevard, Pembroke Pines, FL 33026, USA ([lraez@mhs.net](lraez@mhs.net)) .  \nAbstract  \nBackground: Selpercatinib is a selective RET inhibitor approved for treatment of RET-activated cancers. Adverse events (AEs) are manageable with dose modifications. This post hoc analysis characterized selpercatinib’s clinical safety profile after long-term follow-up in the safety population of LIBRETTO-001.  \nPatients and Methods: LIBRETTO-001 is an ongoing phase I/II, single-arm, open-label trial (NCT03157128) . Eligible patients were ≥18 years old with diagnosis of advanced/metastatic RET fusion-positive solid tumor, RET-mutant medullary thyroid cancer, or other RET-activated tumors. In phase I, patients received selpercatinib 20 mg QD or 20-240 mg BID; patients in phase II received 160 mg BID. The analyzed population comprised all patients who received ≥1 selpercatinib dose and were followed up until data cutoff (January 13, 2023) .  \nResults: For the 837 patients, median follow-up was 45.4 months (95% CI, 44.5-46.6); median time on treatment was 30.1 months (range 0.1- 66.8) . Grade ≥3 treatment-emergent AEs (TEAEs) were reported in 76.2% of patients; most common events were hypertension (19 .7%), ALT increased (11.8%), and hyponatremia (9 .2%) . Serious TEAEs were reported in 51.4% of patients. Most frequently reported any-grade AEs at \u003C6 months of treatment were fatigue (36 .6%), dry mouth (32 .8%), and ALT increased (30 . 5%); at ≥24 months of treatment, these were edema (63 .2%), diarrhea (60 .7%), and fatigue (53 .0%) . Selpercatinib-related TEAEs leading to reduced dosage were reported in 39.3%, those leading to treatment interruption were reported in 47. 1%, and those leading to discontinuation were reported in 4.3% of patients.  \nConclusion: Long-term treatment with selpercatinib is feasible. AEs are manageable with dose modifications, allowing most patients to continue safely on therapy.  \nKey words: selpercatinib; non-small cell lung cancer; medullary thyroid cancer; RET inhibitor; toxicity.  \nImplications for practice  \nResults of this post hoc analysis of LIBRETTO-001 demonstrate that long-term treatment with selpercatinib is feasible. This analysis with additional patients and additional follow-up time shows that adverse events (AEs) occur throughout treatment. These events are reversible or manageable with dose modification, allowing most patients to continue safely on therapy. Awareness of potential AE timing during selpercatinib treatment and patient monitoring is key to managing toxicities.  \nIntroduction  \nRET is a single-pass receptor tyrosine kinase, and alterationsin the RET gene are involved in the pathogenesis of several cancer types. The RET proto-oncogene is generally activated by either fusions or mutations. RET fusions are oncogenicdrivers in 1%-2% of non-small-cell lung cancers (NSCLC)1 and up to 10% of papillary thyroid cancers.2-4 RET mutations occur in 70% of medullary thyroid cancers (MTCs) .5 These  \nalterations result in overexpression and ligand-independent activation of the RET protein as well as downstream pathways involved in cell proliferation and survival.1,6  \nSelective RET inhibitors such as selpercatinib and pralsetinib have been developed to potently inhibit RET in tumors while sparing other kinase and non-kinase of","cbCaitptGflpQazQ","https://ap.wps.com/l/cbCaitptGflpQazQ","pdf",770906,11,"English","# Abstract\n## Background\n## Patients and Methods\n## Results\n## Conclusion\n# Implications for practice\n# Introduction\n# Methods","[{\"question\":\"What was the purpose of this post hoc analysis of LIBRETTO-001?\",\"answer\":\"To characterize the clinical safety profile of selpercatinib after long-term follow-up in the safety population of the LIBRETTO-001 trial.\"},{\"question\":\"How were adverse events distributed by treatment duration?\",\"answer\":\"Any-grade adverse events showed differing patterns over time: common events before 6 months differed from those at ≥24 months, indicating that AE timing evolved during prolonged treatment.\"},{\"question\":\"Were adverse events manageable during long-term therapy?\",\"answer\":\"Yes. The analysis reports that adverse events were generally reversible or manageable with dose modifications, enabling most patients to continue treatment safely.\"}]","Long-term safety of selpercatinib for RET-activated advanced solid tumors in LIBRETTO-001 - differing patterns of adverse events over time | PDF",1790052505,28,[100,104,108,112],{"page_no":22,"url":101,"width":102,"height":103},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a59cebbca7c90ac2ee6acc605a8ce8a4.webp",983,1291,{"page_no":26,"url":105,"width":106,"height":107},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3df75911b1cfe3f4cab3d23f090cd2ef.webp",982,1290,{"page_no":30,"url":109,"width":110,"height":111},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/831b5a0d16fc1dc446dbab3824a85697.webp",981,1289,{"page_no":33,"url":113,"width":114,"height":115},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4a5d4e9e189d88f458257f72c6a0ec63.webp",980,1287,{"code":4,"msg":82,"data":117},[118,122,126,130,135,140,145,148,153,156,159],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":119,"show_sort_weight":120,"slug":121},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":123,"show_sort_weight":124,"slug":125},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":127,"show_sort_weight":128,"slug":129},"Exam",70,"exam",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":133,"slug":134},5,"Comic",60,"comic",{"id":136,"doc_module":4,"doc_module_name":25,"category_name":137,"show_sort_weight":138,"slug":139},6,"Technology",50,"technology",{"id":141,"doc_module":4,"doc_module_name":25,"category_name":142,"show_sort_weight":143,"slug":144},7,"Healthcare",40,"healthcare",{"id":86,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":146,"slug":147},30,"research-report",{"id":149,"doc_module":4,"doc_module_name":25,"category_name":150,"show_sort_weight":151,"slug":152},9,"Religion & Spirituality",20,"religion-spirituality",{"id":151,"doc_module":4,"doc_module_name":25,"category_name":154,"show_sort_weight":151,"slug":155},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":157,"show_sort_weight":55,"slug":158},"Lifestyle","lifestyle",{"id":160,"doc_module":4,"doc_module_name":25,"category_name":161,"show_sort_weight":131,"slug":162},19,"General","general"]